awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41740316-93B912C4-8DDA-4083-BC1E-8573E3E4ABC4
Q41740316-93B912C4-8DDA-4083-BC1E-8573E3E4ABC4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41740316-93B912C4-8DDA-4083-BC1E-8573E3E4ABC4
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.
P2860
Q41740316-93B912C4-8DDA-4083-BC1E-8573E3E4ABC4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41740316-93B912C4-8DDA-4083-BC1E-8573E3E4ABC4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
25a17678923b2407ebbf04033091c4df63eb67fb
P2860
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.